Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Dipexium Pharmaceuticals Inc (DPRX) A Good Stock To Buy?

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the best-performing investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish on. One of their picks is Dipexium Pharmaceuticals Inc (NASDAQ:DPRX), so let’s take a closer look at the sentiment that surrounds it in the current quarter.

Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) shares haven’t seen a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged. The stock was in 8 hedge funds’ portfolios at the end of the third quarter of 2015. It is important to note that the shares of Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) were trading 10.06% higher during the third quarter. This contradictory behavior prompted us to find out more about the hedge funds holding positions in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX), at the end of the last quarter.

At the end of this article, we will also compare Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) to other stocks, including Electro Scientific Industries, Inc. (NASDAQ:ESIO), Daqo New Energy Corp (NYSE:DQ), and Core Molding Technologies, Inc. (NYSEMKT:CMT) to get a better sense of its popularity.

Follow Plx Pharma Inc. (NASDAQ:PLXP)
Trade (NASDAQ:PLXP) Now!

In today’s marketplace, there are many formulas shareholders employ to appraise stocks. A couple of the less utilized formulas are hedge fund and insider trading indicators. Our researchers have shown that, historically, those who follow the best picks of the best hedge fund managers can beat their index-focused peers by a superb amount (see the details here).

With all of this in mind, we’re going to view the key action encompassing Dipexium Pharmaceuticals Inc (NASDAQ:DPRX).

How have hedgies been trading Dipexium Pharmaceuticals Inc (NASDAQ:DPRX)?

At the end of the third quarter, a total of 8 of the hedge funds tracked by Insider Monkey were long this stock, unchanged from the second quarter. With hedgies’ capital changing hands, there exists a few key hedge fund managers who were upping their holdings meaningfully (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Mark Kingdon’s Kingdon Capital has the most valuable position in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX), worth close to $13.7 million, amounting to 0.7% of its total 13F portfolio. Coming in second is Tourbillon Capital Partners, managed by Jason Karp, which holds an $11 million position; the fund has 0.3% of its 13F portfolio invested in the stock. Other members of the smart money that are bullish contain Kevin Kotler’s Broadfin Capital, Anand Parekh’s Alyeska Investment Group, and Ari Zweiman’s 683 Capital Partners.

Judging by the fact that Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) has witnessed a declining sentiment from the smart money, it’s safe to say that there exists a select few money managers who were dropping their positions entirely last quarter. Interestingly, Israel Englander’s Millennium Management dropped the largest position of all the hedgies watched by Insider Monkey, totaling close to $0.4 million in stock. These moves are intriguing to say the least, as aggregate hedge fund interest stayed the same (this is a bearish signal in our experience).

Let’s also examine hedge fund activity in other stocks – not necessarily in the same industry as Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) but similarly valued. These stocks are Electro Scientific Industries, Inc. (NASDAQ:ESIO), Daqo New Energy Corp (NYSE:DQ), Core Molding Technologies, Inc. (NYSEMKT:CMT), and Neff Corp (NYSE:NEFF). This group of stocks’ market caps are similar to Dipexium Pharmaceuticals Inc (NASDAQ:DPRX)’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
ESIO 10 29822 -2
DQ 4 17050 -1
CMT 5 14357 1
NEFF 5 8671 0

As you can see, these stocks had an average of 6 hedge funds with bullish positions and the average amount invested in these stocks was $17 million. That figure was $35 million in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX)’s case. Electro Scientific Industries, Inc. (NASDAQ:ESIO) is the most popular stock in this table. On the other hand, Daqo New Energy Corp (NYSE:DQ) is the least popular one with only 4 bullish hedge fund positions. Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) is not the most popular stock in this group, but hedge fund interest is still above average. This is a slightly positive signal, but we’d rather spend our time researching stocks that hedge funds are piling on. In this regard, Electro Scientific Industries, Inc. (NASDAQ:ESIO) might be a better candidate to consider a long position.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.